美股A股
StockGist
Back
10-Q2026-05-06· grok-4-1-fast-non-reasoning

NAGE · Niagen Bioscience Inc

0001386570-26-000030

SEC filing

Summary

Q1 revenue grew 3.3% to $31.5M driven by e-commerce strength, but operating income fell 67.0% to $1.6M from elevated expenses, partially offset by a one-time gain lifting net income 24.8% to $6.3M.

Key takeaways

Full analysis

Operating income declined sharply to $1.6 million, down 67.0% from $4.8 million, resulting in an operating margin of 5.0%. This pressure reflects investments supporting sales growth, with the full impact on cost structure and margins expected to evolve over the year. Despite the operating decline, net income rose 24.8% to $6.3 million from $5.1 million, driven by a one-time gain that offset core profitability challenges. Diluted EPS improved 16.7% to $0.07 from $0.06, aligning with the net income trend.

Looking forward, future capital requirements will be influenced by cash flows from operations, sales growth, gross margin performance, planned R&D and commercialization investments, and potential strategic initiatives. Certain costs may impact gross margin near-term but are not expected to be material, with limited obligations for product replacements not anticipated to be significant. These dynamics position Niagen to navigate segment-specific pressures while leveraging e-commerce momentum.